A medical device comprises a substrate (10) defining a major surface (9) defining a plane, including a plurality of first struts (14) along a first direction interconnected with a plurality of second struts (12) extending along a second direction not parallel with the first direction, wherein widths (11) of the second struts as measured along the major surface are larger than thicknesses of the second struts as measured perpendicular to the major surface such that when the substrate is stretched in the first direction, intermediate sections (15) of the second struts (12) rotate relative to the first struts (14) and the intermediate sections of the second struts bend out of the plane of the major surface. The medical device is operable to extend and/or retract elements suitable for a particular purpose. The elements are extended and/or retracted in response to a stress applied by way of stretching and/or retracting the device, among other methods. The elements may remain extended and/or retracted or may recoil back to an initial position upon the removal of the force. In various embodiments, the elements are used to treat or deliver treatment to a target site within a body.

The present invention provides a solution to increase the drug loading capacity and drug delivery precision of dissolving microneedles. These solutions include: (a) increasing the base of the microneedle cavities without substantially changing the microneedle's height and geometry, (b) use of drug suspension and sedimentation of drug by centrifugation, and (c) a specific centrifugation order for filling drug and matrix material. In the first preferred embodiment, a microneedle master mould comprising a plurality of pyramidal microneedles (5100), wherein each of the pyramidal microneedles further comprising a chamfered base (5200) which extends to and adjoins with its neighbouring chamfered bases is provided. In the second preferred embodiment, a method of making dissolving microneedles is provided, comprising (a) providing a microneedle template comprising a plurality of pyramidal microneedle cavities, wherein each of the pyramidal microneedle cavities further comprising a chamfered base which extends to and adjoins with its neighbouring chamfered bases; (b) loading a drug suspension in the substrate cavity on the microneedle template; (c) centrifuging the microneedle template which is loaded with a drug suspension, (d) loading a matrix material solution in the substrate cavity on the microneedle template; (d) centrifuging the microneedle template loaded with the drug suspension and the matrix material solution; and (e) drying the centrifuged microneedle template in a controlled environment.

Microneedle patches and systems, and methods for use of such patches and systems. In one aspect, a microneedle patch is provided including a tab portion for handling the microneedle patch. In another aspect, a system is provided including a microneedle patch and a tray for housing the microneedle patch. In still another aspect, various indicators providing for providing feedback prior to, during, and after administration of the microneedle patch are provided. Advantageously, the described microneedle patches and systems provide improved handling and ease of application of the microneedle patches to skin for the delivery of therapeutic agents.

A delivery device or patch is disclosed that includes a detachable hybrid microneedle depot (d-HMND) for cell delivery. The system includes, in one embodiment, an array of microneedles formed from an outer PLGA shell and an internal gelatin methacryloyl (GelMA)-mesenchymal stem cells (MSC) mixture (GMM). The array of microneedles project from a base substrate layer that may be flexible. The therapeutic device may be applied to a tissue site of interest and the base substrate layer is removed leaving the hybrid microneedles in the tissue at the site of application to deliver MSCs. Other stem/therapeutic cells may also be delivered with the hybrid microneedles.

The present invention relates to a cosmetic injector on which microneedles for inducing the absorption of cosmetics are mounted, the injector comprising: an accommodation part for accommodating cosmetics; a head part having a flow path in through which cosmetics flow; a microneedle part which is fixed to the head part, and which is inserted into the skin so as to cause the cosmetics to penetrate the skin; and a pumping part for transferring, to the head part, the cosmetics accommodated in the accommodation part, wherein the head part includes: a first head part for receiving the cosmetics from the pumping part; and a second head part coupled to the upper portion of the first head part, and the microneedle part includes: a microneedle plate provided between the first head part and the second head part; and a plurality of microneedles which extend from the microneedle plate so as to protrude toward the upper surface of the second head part, and which guide, into the skin, the cosmetics discharged from the head part.

Chimeric antigen receptor T cells (CAR T) therapy reached a milestone in eradicating B-cell malignancies, but beneficial effects in solid tumors are not obtained yet. A porous microneedle patch is disclosed that carries CAR T cells to solid tumors (or other cell types). The device is a honeycomb-like porous microneedle patch that accommodates CAR T cells and allows in situ penetration-media seeding of CAR T cells within post-surgical resection of solid tumors. CAR T cells loaded in the pores of the microneedle tips were readily escorted to the tumor in an evenly scattered manner without losing their activity. Such microneedle-mediated local delivery enhanced infiltration and immune stimulation of CAR T cells as compared to direct intratumoral injection. This tailorable patch offers a transformative platform for scattered seeding of living cells for treating a variety of diseases. Other cell types may be loaded into the porous microneedles.

The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

A microneedle assembly and a method of fabrication the assembly are provided. The microneedle assembly includes an array of microneedles attached to a base. Each of the microneedles comprise a tip, a needle shaft and a plurality of cantilevered barbs protruding outwardly from the needle shaft, where a plurality of the microneedles include two or more of the cantilevered barbs arranged in a series of concentric rings along the needle shaft of each of the plurality of microneedles. The microneedle assembly may be fabricated using a 3D printing technique, where one or more cantilevered layers are formed by exposing a photocurable liquid resin including monomer material to a light source to create initially horizontal, cantilevered barbs having a crosslinking gradient, and rinsing to remove an amount of un-crosslinked monomers from the cantilevered layers to induce curvature in the cantilevered barbs extending towards a direction of the lower crosslinking.

Disclosed are a microneedle patch and a method for fabricating the microneedle patch. The microneedle patch includes a base layer including a mesh structure or auxetic materials having a negative Poisson's ratio, and a microneedle array disposed on the base layer. The method includes forming a base layer including a mesh structure or auxetic materials having a negative Poisson's ratio, and forming a microneedle array on the base layer.

Disclosed herein are compositions, devices and methods employing therapeutic concentrations of psilocybin, LSD or MDMA for the treatment of certain health conditions, including depression, anxiety, post-traumatic stress disorder, migraine and cluster headache. Also described are methods and apparatuses to deliver psilocybin, LSD or MDMA by intracutaneous administration via microneedle administration.